TEAD-IN-19

• Description:

  TEAD-IN-19 (Compound 1l) is a transcriptional inhibitor of TEAD, exhibiting inhibition rates of 38.5%, 36.2%, 57.8%, and 71.3% against TEAD1, TEAD2, TEAD3, and TEAD4, respectively, at a concentration of 10 μM. TEAD-IN-19 shows potent anti-proliferative and anti-migratory activities in prostate cancer cell lines and significantly reduces the expression of TEAD-regulated downstream genes. TEAD-IN-19 holds promise for research in the field of cancer therapy[1].

• UNSPSC:

  12352005

• Target:

  YAP

• Related Pathways:

  Stem Cell/Wnt

• Field of Research:

  Cancer

• Smiles:

  CN (C1=CC=CC=C1C (O) =O) C (C=C2) =CC=C2NC (C=C3) =C (Cl) C=C3C4567C89%10C%11%12 (C%10%136 (C) C%14%15%167) C%17%13%16C%11%18%19C%128%20C49%21C%22%155C%18%17%14C%19%20%21%22

• Molecular Formula:

  C33H19ClN2O2

• Molecular Weight:

  510.97

• References & Citations:

  [1]Li C, et al. Discovery and biological evaluation of carborane-containing derivatives as TEAD auto palmitoylation inhibitors. Bioorg Med Chem Lett. 2025 Feb 24;121:130155.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported